Who is sponsoring NCT06257888?

NCT06257888 is sponsored by Renato Cagnacci Neto.

What drugs are being tested in NCT06257888?

Interventions in NCT06257888: patient navigation.

What condition does NCT06257888 study?

NCT06257888 studies Breast Neoplasm Malignant Primary.

Is NCT06257888 still recruiting?

NCT06257888 is currently completed. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT06257888: NAVIMOZ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective Cohort With Patient Navigation as an Intervention for Breast Cancer Patients

Completed Last updated 11 September 2025

What this trial tests

trial testing patient navigation in Breast Neoplasm Malignant Primary in 90 participants. Completed in 1 May 2025.

Timeline

1 March 2024

Primary endpoint
1 April 2025

1 May 2025

Quick facts

Lead sponsor	Renato Cagnacci Neto
Status	Completed
Study type	OBSERVATIONAL
Enrollment	90
Start date	1 March 2024
Primary completion	1 April 2025
Estimated completion	1 May 2025
Sites	1 location across Mozambique

Drugs / interventions tested

patient navigation

Conditions studied

Breast Neoplasm Malignant Primary — all drugs for Breast Neoplasm Malignant Primary →

Sponsor

Renato Cagnacci Neto

Who can join

18 and older, female only, with Breast Neoplasm Malignant Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this observational study is to introduce a patient navigation system within the breast cancer unit at Hospital Central de Maputo (MOZ) and gather data to assess the efficacy of patient navigation in enhancing oncological outcomes among this patient cohort. The primary inquiries it seeks to address are as follows: * Can patient navigation reduce the duration (in days) between patient admission and the commencement of treatment? * Does patient navigation influence overall survival rates when juxtaposed with historical cohorts from the local setting? Participants will receive continuous support from a patient navigator starting from admission until the initiation of any oncological treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Breast Neoplasm Malignant Primary

Currently open trials in the same condition.

NCT06505577 — Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study · recruiting
NCT06310330 — TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06257888 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Renato Cagnacci Neto
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06257888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing